A Phase 1a/1b Study of LY3321367, an Anti-TIM-3 Antibody,Administered Alone or in Combination with LY3300054, an Anti-PD-L1 Antibody, in Advanced Relapsed/Refractory Solid Tumors

Protocol: 
AAAR5271
Phase: 
I

A Phase 1a/1b Study of LY3321367, an Anti-TIM-3 Antibody,Administered Alone or in Combination with LY3300054, an Anti-PD-L1 Antibody, in Advanced Relapsed/Refractory Solid Tumors

The main purpose of this study is to learn more about the study drug called
LY3321367. The study wants to know more about the following:

• The safety of LY3321367 alone and in combination with another drug called
LY3300054 and any side effects you might have

• Whether LY3321367 is tolerable when taken alone and in combination with
LY3300054.

• How much LY3321367 should be given to patients

Are you Eligible? (Inclusion Criteria)

1. Participants must have confirmed solid tumor. Participants must have had
treatment for their disease before.

2. Participants must be in good physical shape. This means that participants
must be able to walk, care for themselves, and do light physical activities
such as light housework or office work.

3. This study is for participants age 18 or older

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States